Wall Street brokerages predict that BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) will report $2.52 million in sales for the current fiscal quarter, according to Zacks Investment Research. Four analysts have made estimates for BioCryst Pharmaceuticals’ earnings, with the highest sales estimate coming in at $7.00 million and the lowest estimate coming in at $440,000.00. BioCryst Pharmaceuticals reported sales of $12.49 million during the same quarter last year, which indicates a negative year-over-year growth rate of 79.8%. The company is scheduled to report its next earnings results on Tuesday, August 6th.

On average, analysts expect that BioCryst Pharmaceuticals will report full-year sales of $16.86 million for the current fiscal year, with estimates ranging from $9.79 million to $27.00 million. For the next financial year, analysts expect that the company will report sales of $42.53 million, with estimates ranging from $20.00 million to $89.46 million. Zacks’ sales calculations are a mean average based on a survey of analysts that that provide coverage for BioCryst Pharmaceuticals.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its earnings results on Wednesday, May 8th. The biotechnology company reported ($0.28) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.28). BioCryst Pharmaceuticals had a negative return on equity of 223.34% and a negative net margin of 472.12%. The business had revenue of $5.89 million for the quarter, compared to analyst estimates of $2.92 million.

A number of equities analysts have weighed in on the company. BidaskClub raised BioCryst Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, April 3rd. Zacks Investment Research downgraded BioCryst Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Monday, April 15th. Jefferies Financial Group decreased their target price on BioCryst Pharmaceuticals from $13.00 to $8.00 and set a “buy” rating on the stock in a research report on Wednesday, May 22nd. ValuEngine downgraded BioCryst Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, May 22nd. Finally, JMP Securities decreased their target price on BioCryst Pharmaceuticals from $18.00 to $10.00 and set an “outperform” rating on the stock in a research report on Thursday, May 23rd. Seven research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average price target of $9.56.

In related news, CFO Thomas R. Staab II sold 9,000 shares of the stock in a transaction that occurred on Monday, May 6th. The stock was sold at an average price of $7.75, for a total transaction of $69,750.00. Following the sale, the chief financial officer now owns 140,426 shares of the company’s stock, valued at $1,088,301.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Thomas R. Staab II sold 9,750 shares of the stock in a transaction that occurred on Friday, May 17th. The stock was sold at an average price of $7.65, for a total value of $74,587.50. Following the sale, the insider now directly owns 134,926 shares in the company, valued at approximately $1,032,183.90. The disclosure for this sale can be found here. Insiders have sold 75,000 shares of company stock worth $583,298 in the last three months. 5.20% of the stock is currently owned by company insiders.

Large investors have recently modified their holdings of the stock. Bank of New York Mellon Corp lifted its holdings in shares of BioCryst Pharmaceuticals by 3.1% during the third quarter. Bank of New York Mellon Corp now owns 420,825 shares of the biotechnology company’s stock valued at $3,211,000 after purchasing an additional 12,544 shares during the last quarter. Vanguard Group Inc. lifted its holdings in shares of BioCryst Pharmaceuticals by 9.2% during the third quarter. Vanguard Group Inc. now owns 5,798,229 shares of the biotechnology company’s stock valued at $44,240,000 after purchasing an additional 490,319 shares during the last quarter. Rhumbline Advisers lifted its holdings in shares of BioCryst Pharmaceuticals by 59.3% during the fourth quarter. Rhumbline Advisers now owns 149,874 shares of the biotechnology company’s stock valued at $1,209,000 after purchasing an additional 55,789 shares during the last quarter. California Public Employees Retirement System lifted its holdings in shares of BioCryst Pharmaceuticals by 24.1% during the fourth quarter. California Public Employees Retirement System now owns 148,673 shares of the biotechnology company’s stock valued at $1,200,000 after purchasing an additional 28,852 shares during the last quarter. Finally, BlackRock Inc. lifted its holdings in shares of BioCryst Pharmaceuticals by 0.9% during the fourth quarter. BlackRock Inc. now owns 8,849,427 shares of the biotechnology company’s stock valued at $71,413,000 after purchasing an additional 79,571 shares during the last quarter. 91.98% of the stock is currently owned by institutional investors and hedge funds.

NASDAQ BCRX traded up $0.05 during trading on Thursday, reaching $3.43. 1,997,655 shares of the company’s stock were exchanged, compared to its average volume of 1,422,163. The company has a market cap of $386.10 million, a PE ratio of -3.50 and a beta of 2.15. The company has a quick ratio of 1.76, a current ratio of 1.77 and a debt-to-equity ratio of 2.38. BioCryst Pharmaceuticals has a fifty-two week low of $2.80 and a fifty-two week high of $9.95.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, discovers oral and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor, for the treatment of acute uncomplicated influenza under the RAPIVAB, ALPIVAB, RAPIACTA, and PERAMIFLU names; and Mundesine, an oral purine nucleoside phosphorylase inhibitor for peripheral T-cell lymphoma.

Featured Article: What Are Treasury Bonds?

Get a free copy of the Zacks research report on BioCryst Pharmaceuticals (BCRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for BioCryst Pharmaceuticals (NASDAQ:BCRX)

Receive News & Ratings for BioCryst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.